Performance of a Novel Research-Use-Only Secretoneurin ELISA in Patients with Suspected Acute Coronary Syndrome: Comparison with an Established Secretoneurin Radioimmunoassay

Peder L. Myhre, Anett H. Ottesen, Arne L. Faaren, Sjur H. Tveit, Jon Springett, Johanna Pyylampi, Mats Stridsberg, Geir Christensen, Arne Didrik Høiseth, Torbjørn Omland, Helge Røsjø

Division of Medicine, Department of Cardiology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division for Research and Innovation, Akershus University Hospital, Lørenskog, Norway; Institute for Experimental Medical Research, Oslo University Hospital, Ullevål, Oslo, Norway; CardiNor, Oslo, Norway; Bioventix, Farnham, UK; Kaivogen, Turku, Finland; Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Keywords
Secretoneurin · Enzyme-linked immunosorbent assay · Acute coronary syndrome

Abstract
Background: Circulating secretoneurin (SN) concentrations, as measured by established radioimmunoassay (RIA), risk stratify patients with cardiovascular disease. We now report data for a recently developed research-use-only SN enzyme-linked immunosorbent assay (ELISA) in patients with suspected acute coronary syndrome (ACS). Methods: SN ELISA was developed according to industry standards and tested in 401 unselected chest pain patients. Blood samples were drawn <24 h from admission, and we adjudicated all hospitalizations as ACS or non-ACS. The mean follow-up was 6.2 years. Results: SN ELISA with 2 monoclonal sheep anti-SN antibodies has a measuring range of 10–250 pmol/L and demonstrates excellent analytical precision and accuracy across the range of SN concentrations. SN measured by ELISA and RIA correlated in the chest pain patients: rho = 0.39, p < 0.001. SN concentrations were higher in ACS patients (n = 161 [40%]) than in non-ACS patients (n = 240) for both assays, with an area under the curve (AUC) of 0.66 (95% CI: 0.61–0.71) for ELISA and 0.59 (0.54–0.65) for RIA. SN concentrations were also higher in nonsurvivors (n = 65 [16%]) than survivors, with an AUC of 0.72 (0.65–0.79) for ELISA versus 0.64 (0.56–0.72) for RIA, p = 0.007, for difference between assays. Adjusting for age, sex, blood pressure, previous myocardial infarction, atrial fibrillation, and heart failure in multivariable analysis, SN concentrations as measured by ELISA, but not RIA, remained associated with mortality, with a hazard ratio of 1.71 (1.03–2.84), p = 0.038. Conclusions: The novel SN ELISA has excellent performance, higher AUC for diagnosis, and superior prognostic accuracy compared to the established RIA in chest pain patients.

Correspondence to:
Peder L. Myhre, p.l.myhre@medisin.uio.no
Helge Røsjø, helge.rosjø@medisin.uio.no
Secretoneurin ELISA in Acute Coronary Syndrome

Introduction

Secretoneurin (SN) is a biologically active fragment of secretogranin II [1], which belongs to the granin protein family [2]. SN directly influences cardiomyocyte Ca\(^{2+}\) handling, and circulating SN concentrations provide prognostic information in patients with acute heart failure [1], cardiovascular-related acute respiratory failure [3], sepsis [4], and ventricular arrhythmia-induced cardiac arrest [1]. Thus, SN represents a promising cardiovascular biomarker that could complement established risk indices and biomarkers.

The pathophysiology reflected by SN as a biomarker is not clear. Early reports suggested that SN is linked to cardiomyocyte Ca\(^{2+}\) handling [5], but SN could also be influenced by additional cardiac pathophysiology. Work in experimental models has demonstrated enhanced SN production by cellular hypoxia [6] and increased myocardial SN concentrations after coronary artery ligation in mice [7]. However, whether myocardial ischemia increases circulating SN concentrations in patients is not known. Moreover, the performance of SN as a prognostic biomarker in patients with suspected acute coronary syndrome (ACS) has not been explored.

The potential of SN as a cardiac biomarker in clinical practice is dependent on an easily available and robust method for SN quantification. To this date, SN has been measured by in-house radioimmunoassays (RIAs) in studies demonstrating improved risk stratification by SN measurements in patients with myocardial dysfunction [1, 3, 4, 8–11]. However, as RIA is time consuming and requires special laboratories due to radiation, there is a need for novel SN assays on platforms more practical for clinical laboratories. Hence, we have recently developed a research-use-only enzyme-linked immunosorbent assay (ELISA) for SN measurements with 2 monoclonal sheep anti-SN antibodies that detect the 33-aminocacid-long SN peptide. Accordingly, in this work, we hypothesized that the novel SN ELISA would provide comparable or superior performance to the established in-house RIA for diagnosis and risk stratification in unselected patients hospitalized with chest pain.

Materials and Methods

Study Design

The Akershus Cardiac Examination (ACE) 3 Study was a prospective, single-center study aiming to assess established and novel cardiovascular biomarkers in unselected patients with chest pain. The study was conducted at the Akershus University Hospital from June 2009 to December 2010. We included all patients aged >18 years with an informed consent, admitted to the emergency department, daytime on weekdays, with chest pain as the primary distress. Exclusion criteria were disseminated malignant disease, acute myocardial infarction, coronary intervention or major surgery during last 2 weeks, inadequate blood sampling, and dementia or other cognitive dysfunction that made informed consent impossible. The study was approved by the Regional Ethics Committee and conducted according to the Declaration of Helsinki.

Data Collection

We collected demographic data, medical history, detailed information on the character and duration of chest pain, vital signs, and medication on hospital admission, during the stay and at discharge. In addition, we obtained clinical information directly from the attending physician in the emergency department with a standardized questionnaire. These included findings from the initial clinical examination, recordings of the electrocardiogram (ECG), and cardiac troponin T (cTnT) concentrations. Assessment of ECGs for indices of acute ischemia was performed, as previously reported [12], based on ESC guidelines [13].

Adjudication of Diagnosis and Follow-Up

The final diagnosis of the index hospitalization was determined by 2 independent senior physicians, who reviewed all medical records during the index hospitalization and follow-up. The reason for chest pain was classified as either ACS or non-ACS. Discrepancy in the adjudication committee was only present in 4% of the cases, and it was resolved by consensus. Diagnosis of acute myocardial infarction was based on criteria defined by the Third Universal Definition of Myocardial Infarction [14] with the use of serial cTnT measurements as part of the clinical routine in the central laboratory (i.e., rise and/or fall of cTnT with at least one value above the 99th percentile upper reference limit of 14 ng/L). We based the diagnosis of unstable angina pectoris on clinical presentation, ECG findings, available examinations (exercise ECG, myocardial scintigraphy, and echocardiography), and coronary angiography (invasive and noninvasive by computer tomography) as recommended by guidelines [15]. The survival status was obtained on December 1, 2016 from electronic hospital records, which are updated with Statistics Norway on a monthly basis.

Biospecimens Collection and Standard Biochemical Analysis

Blood sampling was conducted within the first 24 h of hospital admission in available patients and at day 2 and at the day of discharge. Biospecimens were handled according to a standardized protocol and put on ice prior to centrifugation and later aliquoted into 500 μL cryovials. Samples were kept frozen at −80°C until thawed for biomarker measurements. We collected information on standard biochemical variables from routine measurements, including creatinine, and we calculated the estimated glomerular filtration rate (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [16]. In contrast, we used the study-specific biobank for analysis of cTnT and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. cTnT was measured in the clinical routine and biobank samples by a high-sensitivity (hs) assay (Gen 5 STAT) with a level of blank at 3 ng/L, a 99th percentile upper reference limit of 14 ng/L. The coefficient of variation (CV) was 2.5% at 68 and 3.0% at 925 ng/L (n ≥ 24). Unmeasurable cTnT concentrations were classified as <2 ng/L.
were reported as 3 ng/L. NT-proBNP concentrations were measured using the proBNP II assay. All analyses were performed on the Elecsys platform (Cobas 8000), and the assays and platforms were produced by Roche Diagnostics (Rotkreuz, Switzerland).

**Assays for SN Quantification**

**SN RIA**

SN concentrations were measured by both the in-house SN RIA and SN ELISA. Quantification with SN RIA was performed in 2011–2012 at the Uppsala University Hospital, Sweden, as previously described [17–19]. The RIA has a reported limit of detection for SN in plasma of 50 pmol/L, and the assay has a reported CV of 9% in the lower range (110 pmol/L) and 4% in the upper range (380 pmol/L). Performing the RIA requires days for completion due to the need for incubation prior to SN quantification.

**SN ELISA**

SN was also quantified by a novel research-use-only SN ELISA (CardiNor AS, Oslo, Norway). SN ELISA is a sandwich assay that uses primary and secondary monoclonal sheep anti-SN antibodies (Bioventix, Farnham, UK) with custom-made HRP-conjugated anti-SN antibody for detection (Fleet Bioprocessing, UK). SN ELISA uses a streptavidin-coated microplate, and the biotinylated SN-specific primary antibody (SNNT.2E8) is added to the wells of the micro plate. After washing, the system requires the addition of calibrators, controls, and samples (all diluted 1:10) in duplicate with SN molecules bound by the immobilized primary antibody. Unbound substances are removed, and an HRP-conjugated specific second SN antibody (SNCT.2E8) is added and incubated. The unbound conjugate is removed by washing, and an HRP substrate is added. Finally, the stop solution is added, and the intensity of color developed is measured. A standard linear regression method is used to calculate SN concentrations. We selected antibodies after detailed assessment of antibody performance, including epitope mapping with a system established in our research group [20]. For epitope mapping, we used SPOT peptide arrays to assess where the antibodies bind in the full secretogranin II sequence, which was synthesized as 20-mer overlapping peptides with a 4-amino acid offset on cellulose membranes using a MultiPep automated peptide synthesizer (INTAVIS, Bioanalytical Instruments AG, Co-
logne, Germany) [21]. We included a large number of candidate antibodies for mapping, including the polyclonal rabbit antibodies used for the SN RIA, with results presented in Figure 1. We also validated the results from epitope mapping with testing of antibody affinity for SN by a competition/inhibition ELISA method (see online suppl. Fig. 1; for all online suppl. material describing details of the methodology for the antibody affinity testing, see www.karger.com/doi/10.1159/000517444). The SN ELISA method does not require a pre-analytic incubation period, and the total time for analyzing a batch is 3 h.

**Statistical Analysis**

Baseline characteristics are presented as proportions for categorical variables, mean ± standard deviation for normally distributed continuous variables, and medians (quartile [Q] 1–3) for skewed continuous variables. These characteristics were compared across quartiles of SN using parametric and nonparametric tests, as appropriate. We transformed SN, NT-proBNP, and hs-TnT by the natural logarithm prior to regression analysis due to a right-skewed distribution. Predictors of SN measured by both assays were assessed by multivariable linear regression and correlations by the Spearman rank correlation. The associations between SN measured by the RIA and ELISA and ACS were evaluated by logistic regression analysis and by calculating receiver-operating statistics area under the curve. We evaluated the association between SN measured by both assays and all-cause mortality by Cox proportional hazard regression analysis in (1) an unadjusted analysis, (2) after adjustment for age and sex; (3) after additional adjustment for hypertension, atrial fibrillation, heart failure, and previous myocardial infarction; and (4) after additional adjustment for eGFR and hs-TnT. The prognostic accuracies of SN measured by the RIA and ELISA were also calculated and compared by Harrell’s C-statistics. We used the Kaplan-Meier method to present survival plots according to quartiles of SN measured by each assay. Statistical analysis was performed using STATA software v15.1 (StataCorp, College Station, TX, USA). A 2-sided p value <0.05 was considered significant.

**Results**

**Antibody Testing and SN ELISA Characterization**

All of the antibodies tested were found to be specific for the SN region of secretogranin II during epitope mapping (Fig. 1). The antibodies SN-NT (SgII 154–165), SNNT.2E8, SNNT.6A9, and SNNT.7F3 bind to the N-terminal end of SN, while SN-CT (SgII 172–186), SNCT.3A7, SNCT.3B7, SNCT.6B12, and SNCT.6F10 bind to the C-terminal end of SN. The antibody SNNT.4E2 seems to bind both the N-terminal and the C-terminal end of SN. Testing of antibody affinity demonstrated similar binding properties for the candidate antibodies as identified during epitope mapping (online suppl. Fig. 1).

Testing of SN sandwich ELISA with SNNT.2E8 and SNCT.3B7 demonstrated that the range of SN concentration that can be detected by SN ELISA is 10–250 pmol/L (online suppl. Fig. 2), showing linearity across the measuring range (see online suppl. Tables 1, 2; and online suppl. Fig. 3). The level of quantification was 2.3 pmol/L (estimated as mean value of buffer blank plus 10 standard deviations of the mean expressed in analyte concentration) is well below the measuring range (details in online suppl.). The SN ELISA demonstrates excellent intra-assay and inter-assay CVs, <5 and <7%, respectively (online suppl. Table 3).

**Patient Characteristics in the ACE 3 Study**

Among the 401 patients included in the study, the mean age was 61 ± 15 years and 191 (48%) were female. The prevalence of cardiovascular comorbidities was 134 (34%) for hypertension, 44 (11%) for diabetes mellitus, 86 (22%) with a previous myocardial infarction, 60 (15%) for atrial fibrillation, and 21 (5%) with heart failure. Median (Q1–Q3) SN concentrations in the total population were 127 (110–148) pmol/L as measured by the RIA and 30.1 (25.3–36.8) pmol/L as measured by ELISA. The correlation coefficient between SN measured by the RIA and ELISA was 0.39, p < 0.001. Baseline characteristics according to quartiles of SN ELISA are presented in Table 1. A higher quartile of SN ELISA was associated with older age, lower BMI, higher heart rate, more frequent ischemia on ECG, comorbidities and cardiovascular preventive medications, higher hs-TnT and NT-proBNP concentrations, and lower eGFR.

SN concentrations, as measured by both the RIA and ELISA, correlated with several important cardiovascular risk factors and biomarkers, including hs-TnT and NT-proBNP (online suppl. Table 4). Still, in multivariable linear regression analysis, only eGFR (t = −8.0, p < 0.001) and NT-proBNP (t = 3.9, p < 0.001) remained associated with SN ELISA, and these explained 29% of the variation in SN ELISA (r² = 0.29). Analogously, eGFR (t = −4.5, p < 0.001), NT-proBNP (t = 3.4, p = 0.001), and age (t = −2.7, p = 0.008) were associated with SN RIA in multivariable models, and these explained 10% of the variation in SN ELISA (r² = 0.10).

**SN in Diagnosing ACS**

ACS was diagnosed in 161 of the 401 chest pain patients included in this study (40% of the total population). Among the patients classified with ACS, 73 patients were diagnosed with acute myocardial infarction (45%) and 88 patients with unstable angina pectoris.

Patients with ACS were older, had more comorbidities, and more frequently used preventive medications compared to patients without ACS. A diagnosis of ACS
was associated with higher hs-TnT, NT-proBNP, and SN concentrations, as measured by both the ELISA and RIA (Table 2). Greater concentrations of SN ELISA were associated with ACS in unadjusted models (odds ratio: 2.05 [95% confidence interval [CI]: 1.32–2.78] per log unit increase, \( p < 0.001 \)) with an AUC of 0.66 (0.61–0.71). Similarly, greater concentrations of SN RIA were associated with ACS in unadjusted models (odds ratio: 0.99 [95% CI: 0.20–1.79] per log unit increase, \( p = 0.014 \)) with AUC 0.59 (0.54–0.65). The diagnostic accuracy of hs-TnT to diagnose ACS patients in our study was an AUC of 0.82 (0.78–0.86).

**SN in Predicting All-Cause Mortality**

During a mean 6.2 ± 1.5-year follow-up, 65 (16%) of the patients died and 49 (75%) of these were classified with ACS as the cause of the index hospitalization. SN measured by ELISA was associated with time to all-cause mortality (hazard ratio: 2.64 [95% CI: 1.94–3.60] per log unit increase, \( p < 0.001 \)), with a corresponding Harrell’s C-statistics of 0.72 (95% CI: 0.65–0.79). The prognostic performance of SN ELISA persisted after adjusting for demographics (\( p = 0.014 \)) and comorbidities (\( p = 0.03 \)) but not after further adjustments for eGFR and hs-TnT (\( p = 0.58 \)) (Table 3). SN measured by the RIA was also associated with time to all-cause mortality (hazard ratio: 4.13 [95% CI: 2.15–7.92] per log unit increase, \( p < 0.001 \)), with a Harrell’s C-statistics of 0.64 (95% CI 0.56–0.72), which was significantly lower than that for SN ELISA (\( p = 0.007 \), for difference between SN assays). The prognostic performance of SN RIA was attenuated after adjusting for age and sex and was no longer significant (\( p = 0.20 \)). Survival curves by quartiles of SN measured by ELISA and RIA are presented in Figure 2.

### Table 1. Baseline characteristics by quartiles of SN measured by ELISA

|                  | SN Q1 (n = 101) | SN Q2 (n = 101) | SN Q3 (n = 102) | SN Q4 (n = 98) | \( p \) |
|------------------|-----------------|-----------------|-----------------|----------------|------|
| SN range, pmol/L | 13.4–25.2       | 25.3–30.1       | 30.2–36.8       | 36.9–97.6      | (+840 in one outlier) |
| Age, years       | 52.6±12.4       | 59.3±14.3       | 62.2±13.8       | 70.7±13.8      | <0.001 |
| Male sex, n (%)  | 60 (60.0)       | 52 (51.5)       | 55 (53.9)       | 43 (43.9)      | 0.042 |
| BMI              | 30.4±5.9        | 27.2±4.0        | 26.7±4.2        | 25.0±4.1       | <0.001 |
| Systolic blood pressure | 148±24 | 151±26 | 149±25 | 147±31 | 0.67 |
| Heart rate       | 74±19           | 73±16           | 73±18           | 84±27          | 0.003 |
| ECG acute ischemia, n (%) | 13 (13.0) | 16 (15.8) | 19 (18.6) | 26 (26.5) | 0.013 |
| ECG QRS width    | 101±16          | 99±18           | 99±20           | 102±24         | 0.71 |
| Medical history, n (%) |               |                 |                 |                |      |
| Hypertension     | 26 (26.0)       | 31 (31.0)       | 33 (32.4)       | 44 (44.9)      | 0.006 |
| Heart failure    | 0 (0.0)         | 6 (6.0)         | 4 (3.9)         | 11 (11.2)      | 0.002 |
| Atrial fibrillation | 12 (12.0) | 11 (11.0) | 10 (9.8) | 27 (27.6) | 0.005 |
| Myocardial infarction | 18 (18.0) | 11 (11.0) | 24 (23.5) | 33 (34.0) | 0.001 |
| Coronary revascularization | 20 (20.0) | 17 (17.0) | 25 (24.5) | 30 (30.6) | 0.038 |
| Medication       |                 |                 |                 |                |      |
| Aspirin          | 35 (35.0)       | 30 (29.7)       | 38 (37.3)       | 52 (53.1)      | 0.005 |
| Statin           | 37 (37.0)       | 37 (36.6)       | 44 (43.1)       | 56 (57.1)      | 0.003 |
| RAS inhibitors   | 26 (26.0)       | 24 (23.8)       | 34 (33.3)       | 47 (48.0)      | <0.001 |
| Beta-blocker     | 28 (28.0)       | 31 (30.7)       | 42 (41.2)       | 56 (57.1)      | <0.001 |
| Diuretics        | 5 (5.0)         | 7 (6.9)         | 9 (8.8)         | 31 (31.6)      | <0.001 |
| Laboratory       |                 |                 |                 |                |      |
| Hemoglobin, g/dL | 14.4 (13.2, 15.0) | 14.0 (13.1, 14.8) | 13.8 (12.7, 15.2) | 13.4 (12.1, 14.7) | <0.001 |
| C-reactive protein, mg/L | 5 (5, 8) | 5 (5, 5) | 5 (5, 5) | 5 (5, 10) | 0.29 |
| eGFR, mL/min/1.73 m² | 92 (81, 102) | 88 (76, 100) | 81 (68, 95) | 59 (47, 83) | <0.001 |
| Total cholesterol, mmol/L | 5.1 (4.4, 5.9) | 5.4 (4.3, 6.1) | 5.0 (4.1, 6.1) | 5.1 (4.3, 5.8) | 0.57 |
| LDL cholesterol, mmol/L | 3.1 (2.3, 3.8) | 3.1 (2.3, 3.9) | 2.8 (2.2, 3.8) | 2.8 (2.0, 3.5) | 0.10 |
| Cardiac troponin T, ng/L | 3 (3, 4) | 3 (3, 13) | 4 (3, 13) | 12 (3, 40) | <0.001 |
| NT-proBNP, ng/L | 74 (34, 174) | 110 (54, 254) | 178 (52, 607) | 491 (143, 2384) | <0.001 |

RAS, renin-angiotensin-system; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SN, secretoneurin.
**Discussion**

We report details of a novel research-use-only SN ELISA that has excellent performance and very good precision across different SN concentrations. SN ELISA also provided superior prognostic information compared to the established SN RIA in unselected patients hospitalized for chest pain.

Novel biomarkers should meet the following 3 key characteristics to have clinical potential: (1) there should be a robust and easily available method for biomarker measurement, (2) the biomarker should provide increased...
mental information to established risk indices and biomarkers, and (3) the biomarker should influence patient management [22]. So far, SN has been found to provide incremental prognostic information to established risk indices in patients with acute heart failure, ventricular arrhythmia-induced cardiac arrest, cardiovascular-related respiratory failure, cardiac surgical patients [9, 23], and in patients with severe infections [10, 11]. However, these data have all been produced by an in-house SN RIA, which cannot easily be transferred to a routine clinical chemistry laboratory for day-to-day use. Hence, the development of an easy-to-use SN ELISA is a step forward for SN as a candidate cardiovascular biomarker by fulfilling the criteria related to biomarker analysis. This novel method of measuring SN is substantially more time-efficient, and with potential for later conversion to large-scale automated ELISA instruments. Our detailed characterization of the 2 monoclonal sheep antibodies selected for the assay and the excellent performance of SN ELISA across a range of SN concentrations support that this assay will be valuable for future studies on SN as a cardiovascular biomarker. SN concentrations measured with ELISA and RIA demonstrated acceptable correlation, especially considering the long storage of samples between RIA and ELISA analyses. Moreover, as correlation coefficients for SN ELISA and hs-TnT and SN ELISA and NT-proBNP were in the same range, as previously reported for SN RIA [1, 3, 4, 9, 23], we consider SN ELISA an attractive alternative to the established RIA for SN quantification.

SN measurements have previously been found to improve risk assessment across different populations with myocardial dysfunction [1, 3, 4, 8–11]. In contrast, SN concentrations did not improve diagnosis of heart failure over NT-proBNP measurements in unselected patients hospitalized with acute dyspnea [1]. We now extend the data on SN as a cardiovascular biomarker to a new population of low-risk chest pain patients. In line with the current model of SN as a prognostic cardiovascular biomarker, SN provided prognostic information in patients with chest pain that was independent of demographics and comorbidities but not incremental to cTnT. While SN has been shown to provide prognostic information on top of cTnT and NT-proBNP in other clinical settings [1, 3, 4, 9–11], the central role of these biomarkers in ACS, and the modest statistical power in the current population, may account for the lack of prognostic independence for SN in this cohort of low-risk chest pain patients. Although SN concentrations were higher in patients with ACS, the diagnostic performance in chest pain patients was limited and not clinically useful. Hence, SN could have prognostic potential in low-risk, unselected chest pain patients but is not a candidate biomarker to diagnose acute myocardial injury and necrosis in chest pain patients. Of relevance for this study, the recently developed SN ELISA provided superior prognostic accuracy to the established SN RIA. As demonstrated in Figure 2, patients with the highest SN concentrations (quartile 4) had a poor prognosis with both assays. In contrast, only the SN ELISA seemed to identify high-risk patients also in quartile 3, which could relate to superior precision of the SN ELISA in only slightly elevated SN concentrations. The reported AUC of the SN ELISA to predict mortality in these low-risk chest pain patients was comparable to AUCs previously reported for the SN RIA in more high-risk patients, such as patients with acute heart failure, cardiovascular-related respiratory failure, cardiac surgical patients [9, 23], and with severe infections [10, 11]. However, whether SN can improve risk assessment over established risk indices and cardiac biomarkers in low-risk chest pain patients will need to be tested in larger cohorts with more events than the current population.

Currently, the pathobiology reflected by high SN concentrations in patients with myocardial dysfunction is not fully established. Although we find higher SN concentrations for chest pain patients with coronary artery disease than patients with non-ACS-related chest pain, there was a large overlap in SN concentrations between these groups as reflected in AUCs of 0.66 and 0.59 for SN ELISA and SN RIA, respectively. The minor impact by acute myocardial ischemia and necrosis on circulating SN concentrations excludes SN as a diagnostic biomarker in chest pain patients, which is not surprising as SN is produced in different organs throughout the body [18]. Pertinent to this point, our study supports SN as an index of cardiac and noncardiac pathobiology during myocardial dysfunction as both eGFR and hs-TnT were independently associated with higher SN concentrations in multivariable linear regression analysis. Still, our study did not find acute myocardial injury and necrosis to represent strong stimuli for high SN concentrations in patients, and therefore, future studies should assess additional cardiac pathobiology as stimuli for high SN concentrations in situations of myocardial dysfunction.

This study has some strengths and limitations. We believe the detailed characterization of the monoclonal sheep antibodies represent a strength for the novel SN ELISA. We have also included unselected patients with chest pain and performed biomarker testing according to standard statistical criteria for diagnostic and prognostic utility, including benchmarking against cardiac biomark-
ers already in clinical use. Limitations of the current study include a relatively low number of patients in a low-risk cohort, moderate duration of follow-up, and lack of information on the specific cause of death in our patients.

Conclusion

We provide detailed data on a novel research-use-only SN ELISA with excellent performance and very good precision across a range of SN concentrations. The SN ELISA also demonstrated higher AUC for diagnosis and superior prognostic accuracy compared to the established RIA in unselected chest pain patients, but whether the SN ELISA may provide incremental prognostic information to established risk indices and biomarkers in low-risk chest pain patients will have to be tested in additional studies with larger cohorts and more events.

Acknowledgments

We thank study personnel and physicians at the Akershus University Hospital that participated in the inclusion of patients in the ACE 3 Study. We are also grateful for help from research coordinator Ronja Hesthammer, Ph.D, Division of Research and Innovation, Akershus University Hospital.

Statement of Ethics

The current study was approved by the Regional Medical Ethics Committee (#6.1008.2827) and conducted in accordance with the Helsinki Declaration. All participants provided written informed consent.

Conflict of Interest Statement

P.L.M. has served on advisory boards for Novartis and Novo Nordisk and has received consulting honoraria from Novartis, AmGen, and Novo Nordisk. M.S., G.C., T.O., and H.R. are partners in a patent regarding the use of SN as a biomarker in cardiovascular disease and in patients with critical illness. M.S., G.C., A.L.F., T.O., and H.R. are stock owners in CardiNor AS, which holds the license to commercialize secretoneurin. A.H.O., A.L.F., M.S., T.O., A.H.O., and H.R. have also received personal payments from CardiNor AS. T.O. has served on advisory boards and received speaker’s honoraria and travel funding from Roche Diagnostics and Roche Diagnostics that provided hs-TnT and NT-proBNP kits at a reduced price via the Akershus University Hospital. T.O. and H.R. have received personal fees from Novartis and Thermo Fisher BRAHMS. J.S. and J.P. are employees of Bioventix and Kaivogen, respectively, and both of these companies are involved in production and sale of the SN ELISA. The remaining authors have no disclosures and report no conflicts of interest pertaining to this work.

Funding Sources

Dr. Myhre is supported by a research grant from the South-Eastern Norway Regional Health Authority to Dr. Røsjø, and Dr. Ottesen is supported by a research grant from the Norwegian Research Council to Dr. Røsjø.

Author Contributions

P.L.M. performed the clinical analysis from the ACE3 study and drafted the manuscript. A.H.O. performed the experimental SN analysis and drafted the manuscript. A.L.F., J.S., J.P., and M.S. participated in the development of SN ELISA. S.T. and A.D.H. participated in the data collection in the ACE3 study. G.C., T.O., and H.R. designed and supervised the study. All the authors critically reviewed the manuscript.

Secretoneurin ELISA in Acute Coronary Syndrome

DOI: 10.1159/000517444

573
10 Røsjø H, Masson S, Caironi P, Stridsberg M, Magnoli M, Christensen G, et al. Prognostic value of secretoneurin in patients with severe sepsis and septic shock: data from the albumin Italian outcome sepsis study. Crit Care Med. 2018 May;46(5):e404–e10.

11 Røsjø H, Nygård S, Kaukonen KM, Karlsson S, Stridsberg M, Ruokonen E, et al. Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study. Intensive Care Med. 2012 May;38(5):820–9.

12 Tveit SH, Myhre PL, Hoff NJS, Le TM, Seljeflot I, Rausland R, et al. Superiority of high sensitivity cardiac troponin T vs. I for long-term prognostic value in patients with chest pain: data from the akershus cardiac examination (ACE) 3 study. Clin Biochem. 2020 Apr;78:10–7.

13 Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011 Dec;32(23):2999–3054.

14 Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012 Oct 16;60(16):1581–98.

15 Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267–315.

16 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604–12.

17 Stridsberg M, Eriksson B, Janson ET. Measurements of secretogranins II, III, V and pro-convertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regul Pept. 2008 Jun 5;148(1–3):95–8.

18 Rosjo H, Stridsberg M, Florholmen G, Stenslokken KO, Ottesen AH, Sjaastad I, et al. Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties. PLoS One. 2012;7(5):e37401.

19 Myhre PL, Ottesen AH, Okkonen M, Linko R, Stridsberg M, Nygard S, et al. Prognostic value of secretoneurin in patients with acute respiratory failure: data from the FINNALI Study. Clin Chem. 2016;62(10):1380–9.

20 Røsjø H, Husberg C, Dahl MB, Stridsberg M, Sjaastad I, Finsen AV, et al. Chromogranin B in heart failure: a putative cardiac biomarker expressed in the failing myocardium. Circ Heart Fail. 2010 Jul;3(4):303–11.

21 Frank R, Overwin H. SPOT synthesis. Epitope analysis with arrays of synthetic peptides prepared on cellulose membranes. Methods Mol Biol. 1996;66:149–69.

22 Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007 Feb 27;115(8):949–52.

23 Brynildsen J, Petäjä L, Myhre PL, Lyngbakken MN, Nygård S, Stridsberg M, et al. Circulating secretoneurin concentrations after cardiac surgery: data from the FINNish acute kidney injury heart study. Crit Care Med. 2019 May;47(5):e412–e19.